key: cord-0018411-pd701ma9
authors: Hanley, Sharon J.B.
title: Towards the elimination of cervical cancer in Japan
date: 2021-05-28
journal: J Gynecol Oncol
DOI: 10.3802/jgo.2021.32.e76
sha: 262d43134e4b265d9edb4c79d2450093c99ae919
doc_id: 18411
cord_uid: pd701ma9

nan

adopted by the World Health Assembly, which is comprised of 194 Member States, including Japan. Elimination is defined as a threshold of <4/100,000 women diagnosed with cervical cancer annually [3] . To achieve this goal by the end of the 21st century, the global strategy contains three pillars, each with their own associated targets that should be achieved by 2030: 1. Fully vaccinating 90% of girls against HPV by the age of 15 years; 2. Screening 70% of women with a high-performance (HPV) test by the age of 35 years and once again by the age of 45 years; and 3. Treating and managing 90% of women identified with cervical disease [3] .

At present, Japan only achieves the third global elimination goal ( Fig. 1) which raises concerns over the effectiveness of current cervical cancer control measures. Why has this occurred and what needs to be done for Japan to achieve elimination of cervical cancer as a public health problem by the end of the century?

The bivalent HPV vaccine was licenced in Japan in October 2009 and the quadrivalent vaccine in July 2011 [4] . From December 2010, special funding was provided for girls aged 12-16 years whereby the national government paid 50% of the vaccine cost, if local government also paid 50%. Uptake was high with three-dose coverage reaching over 70% [4] . From April 1, 2013, both HPV vaccines were included into the Japanese national immunization program (NIP) and were provided free for girls aged 12-16 years. However, soon after the announcement that the vaccine would be included in the national program, unconfirmed reports of adverse events following immunization began to appear in the media and emotive images of girls having difficulty walking or controlling their movements were broadcast extensively in the media [5] . In June 2013, only two months after inclusion in the NIP, the Ministry of Health, Labour, and Welfare announced that, although the vaccine would remain in the NIP and would be free for 12-16-year-old girls, all proactive recommendations for it would be suspended. Over the past eight years, several large-scale epidemiological studies conducted in Japan have shown that the HPV vaccine is effective against both HPV infection [6] and precancerous disease [7, 8] , and safe [9] . However, as of May 2021, the situation remains unchanged, with the vaccine still available for free to the target age groups but not being proactively recommended. After the suspension of proactive recommendations, vaccination coverage decreased sharply, from >70% to <1% and coverage has remained at less than 1% to date [4, 10] .

Cytology-based cervical screening began in Japan in the late 1950s. Before 1998, the national government was responsible for cancer control activities [11] . From 1998, due to economic reasons, the financial burden of cancer control was moved to prefectural governments. As a result, the Health and Medical Services for the Elderly Act, transferred responsibility from the central level to prefectural and municipal levels [11, 12] . Preventative medicine is not included in the National Health Insurance System, so screening activity and vaccination are funded directly by each municipality [13] . Japanese women have multiple opportunities to be screened for cervical cancer, these include: screening organized by municipalities (free or for a small charge); individual screening at a gynecologist's clinic (around 70% of fee covered by the national health insurance system); screening as part of a workplace health check-up (cervical 2/5 https://ejgo.org https://doi.org/10.3802/jgo.2021.32.e76

screening is an add-on option for a small fee) or screening as part of a comprehensive health check-up (ningen-dock, not covered by national health insurance but may be subsidized by the workplace) [11, 13] However, cervical screening is predominantly opportunistic, and since there is no national screening program, accurate estimates of coverage are difficult to ascertain. Data from the Comprehensive Survey of Living Conditions, which randomly samples 290,000 households from 5,410 districts nationwide, is normally cited for biennial cervical screening coverage. Data from the 2019 survey suggests that only 43% of women aged between 20-69 years underwent cervical screening in the past 2 years [14, 15] .

Due to the absence of a systematic monitoring system, treatment rates for cervical cancer are also difficult to estimate in Japan. However, while the ASIR of cervical cancer in Japan is higher than the global ASIR, as well as many LMICs in the Asia Pacific region [1] , universal access to health care means mortality rates are much lower: 8.3 and 6.7 per 100,000 in Cambodia and Bangladesh, respectively, compared to 2.9 per 100,000 in Japan (Fig. 1 ) [1] .

Five-year survival rates for cervical cancer are also comparable or better than other highincome countries: 75.7% in Japan [16] , compared to 73.5%, 66.0%, and 61.4% in Australia [17] , the US [18] and England [19] respectively, suggesting women who do need follow-up are adequately treated and managed.

Because of the wide-ranging influence of the Internet and social media, suspension of proactive recommendations for the HPV vaccine not only resulted in a decrease in vaccine uptake in Japan, but also likely contributed to a decrease in coverage in other countries such as Denmark and Ireland [20, 21] . However, despite the negative media coverage, the Danish and Irish governments and medical professionals continued to proactively promote HPV vaccination and as a result, uptake recovered to previous levels [20, 22] . One Japanese study investigating correlates of HPV vaccine acceptance in mothers with adolescent daughters found that recommendation from a physician or the local health board were strong motivators for mothers to get their daughter vaccinated [23] . Therefore, immediate resumption of proactive recommendations for the HPV vaccine by the Ministry of Health, Labour and Welfare is essential to increase public confidence in the HPV vaccine and increase coverage. However, vaccination alone is not enough, a recent modelling study found that even if coverage could recover to previous rates, even using the 9 valent vaccine, Japan would still not achieve the elimination threshold of >4 cases per 100,000 women by the end of the century. Increase in screening coverage is also essential [14] .

Screening guidelines are developed by the Japanese Advisory Committee on Cancer Screening and implemented by local government [12] . Currently, biennial cervical cancer screening using the Pap smear with reflex HPV testing for atypical squamous cells of undetermined significance in women aged >20 years is recommended [13] . The guidelines Towards the elimination of cervical cancer in Japan were updated in 2020 and now also recommend 5 yearly physician-led primary HPV testing [24] . As well as the extended screening intervals, one advantage of HPV testing is that it can also be performed on self-collected samples with similar accuracy to a clinician led sample [25] . HPV self-sampling has been found to be highly acceptable by women across a range of cultural settings, including Japan [26, 27] . Empowering women to take their own samples may be one way to increase cervical screening coverage in Japan.

Despite having the tools, knowledge and wealth to prevent, diagnose and treat cervical cancer, Japan is not on track to eliminate cervical cancer as a public health problem by the end of the century. To rectify this, high level political support is also necessary. During his call to eliminate cervical cancer, Dr. Tedros Adhanom Ghebreyesus declared 'When we have the weapons at hand, failure should not be an option'. Sadly, the present lack of resolution by the Japanese government, particularly towards the HPV vaccine, will result in a high number of preventable cervical cancers. The Japanese government must act now so that failure is not an option.

Lyon: International Agency for Research on Cancer; c2020

Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries

Global strategy to accelerate the elimination of cervical cancer as a public health problem

HPV vaccination crisis in Japan

Trends of media coverage on human papillomavirus vaccination in Japanese newspapers

Bivalent human papillomavirus vaccine effectiveness in a Japanese population: high vaccine-type-specific effectiveness and evidence of cross-protection

Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women

Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: a nationwide case-control study

No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study

Health consciousness and cervical cancer screening rates in HPV-unvaccinated girls: comparison from HPV-recommended and HPVrecommendation-suspended program periods

Challenges in breast and cervical cancer control in Japan

The standardized development method of the Japanese guidelines for cancer screening

The Japanese guideline for cervical cancer screening

Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study

Japanese Ministry of Health, Labour and Welfare. Comprehensive survey of living conditions

Japanese Ministry of Health, Labour and Welfare; c2013

Tokyo: Cancer Information Service; c2021

Sydney: Cancer Council; c2019

VA: Cancer Net; c2021

Cervical cancer age-standardised one-, five-and ten-year net survival, adults (aged 15-99)

Rapid response to HPV vaccination crisis in Ireland

Decline in HPVvaccination uptake in Denmark -the association between HPV-related media coverage and HPVvaccination

Resilience of HPV vaccine uptake in Denmark: decline and recovery

Acceptance of and attitudes towards human papillomavirus vaccination in Japanese mothers of adolescent girls

Tokyo: National Cancer Center Japan; c2020

Castle PCollaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses

HPV self-sampling in Japanese women: a feasibility study in a population with limited experience of tampon use

Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis